Evidence map›Paper›PMID 36102417›Full record

ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2022

Convalescent plasma therapy in COVID-19 patients: a non-randomized case-control study with concurrent control.

P Cacilhas, E Caberlon, L Angoleri, K Fassina, R N Ribeiro, L C Pinto

Abstract read
In one paragraph

Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

P CacilhasHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0002-5370-3514
E CaberlonHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0001-8798-226X
L AngoleriHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0002-1649-1137
K FassinaHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0002-0171-4916
R N RibeiroHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0001-5862-3030
L C PintoHospital Nossa Senhora da Conceição, Porto Alegre, RS, Brasil.ORCID http://orcid.org/0000-0003-0954-8622

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Convalescent plasma therapy has shown controversial results in coronavirus disease-19 (COVID-19) patients. We performed a non-randomized case-control study with contemporaneous controls in a hospital in southern Brazil. Patients were selected for treatment with convalescent plasma by medical decision and compared with patients who did not receive plasma and were hospitalized due to COVID-19 at the same time. The outcomes of interest were intensive care unit (ICU) admission and in-hospital death. Patients that received convalescent plasma had lower in-hospital mortality than patients that did not receive plasma (relative risk (RR) 0.48; 95% confidence interval (CI) 0.29 to 0.79) and these results were consistent after changing the subset of control patients. There were no differences regarding ICU admission between groups (RR=0.80; 95%CI: 0.47 to 1.35). In this study, patients that received convalescent plasma for COVID-19 had lower in-hospital mortality, but this finding requires further confirmation given the retrospective nature of the study.

Indexed as

COVID-19Case-Control StudiesCOVID-19 SerotherapyHospital MortalityHumansImmunization, PassiveRetrospective Studies

Identifiers

PMID36102417
PMCPMC9467281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.